Hardly any sentence appears as reliably in the debate about cannabis partial legalization as this one: politics is downplaying drug use, and the rise in drug deaths is the price for it. A look at official statistics shows that this connection doesn’t hold up. An analysis.
📑 Inhaltsverzeichnis
- What the drug death statistics actually show
- The actual driver: synthetic opioids
- One report, two interpretations
- Why the argument is politically so appealing
- What concerns remain justified
- Why regulation is a safety argument
- International perspective
- Conclusion: Debating what matters
- 💬 Fragen? Frag den Hanf-Buddy!
Since the Cannabis Consumption Act (KCanG) came into force in April 2024, a recurring argument has accompanied criticism of it: whoever legalizes cannabis downplays drugs in general, and the rising number of drug deaths in Germany is the consequence. This is formulated across opinion pieces and political statements, for example in demands from the Union to abolish the law again. With the second interim report on the evaluation of the law, presented on April 1, 2026, the debate has gained new momentum. Reason enough to take a closer look at the central figure of this narrative: who dies in Germany from drugs, and from what?
What the drug death statistics actually show
In 2025, 2,150 people died in Germany from the consequences of their drug use, compared to 2,137 in the previous year. The average age of the deceased was 40.6 years, with roughly a quarter younger than 30. Particularly alarming: in the group of those under 30, deaths have increased by 53 percent since 2021, and in those under 20, they have nearly doubled.
Crucially, which substances were detected in these deaths. Because many of the deceased had consumed multiple substances simultaneously, multiple mentions are the rule:
- Opiates and opioids: 1,316 cases
- Cocaine and crack: 769 cases
- Heroin and morphine: 708 cases
- Psychoactive medications: 696 cases
- Opioid substitution drugs: 611 cases
- Amphetamines: 602 cases
- Fentanyl: 118 cases
The curve of drug deaths is driven by opioids, cocaine, and a growing number of synthetic substances. Cannabis does not appear in this breakdown as a cause of death. This is not a statistical oversight, but reflects medical knowledge: a fatal overdose caused solely by cannabis has not been documented. The accusation that rising death numbers are the price of „cannabis downplaying“ thus links two things that have nothing to do with each other statistically.
The actual driver: synthetic opioids
Those who take young deaths seriously must talk about other substances. The Federal Government’s Commissioner for Addiction and Drug Issues, Hendrik Streeck, warns of pills that look like known medications but are laced with highly potent synthetic opioids like nitazenes. In younger victims especially, concurrent use of medications and unknown-composition substances plays a central role. It is precisely here, in the uncontrolled market for opioids and counterfeit pills, that the lethal risk lies—not in the regulated distribution of cannabis.
One report, two interpretations
Remarkably, the second evaluation report (EKOCAN) is interpreted quite differently. The Federal Government emphasizes problem areas in its assessment. Health Minister Nina Warken points to unregulated online products with „extremely high THC content“ targeting young people. Interior Minister Alexander Dobrindt calls the law „crime-promoting“ and claims that the „black market is booming, crime is rising.“ Family Minister Karin Prien notes that participation in early intervention programs is declining significantly.
Other analyses of the same data provide a more cautious picture. They point out that an increase in consumption is neither proven among adults nor adolescents and that the number of cannabis-related crimes has declined significantly. An analysis by the German Institute for Economic Research puts the decline in cannabis-related offenses from around 174,000 in 2023 to approximately 62,000 in 2024, primarily due to eliminated possession and consumption offenses. At the same time, legal supply remains expandable: nationwide, only around 366 cultivation associations have been approved, significantly fewer than demand suggests, which continues to leave room for the black market.
The evaluation mandate itself is deliberately broadly designed. The effects of the law on child and youth protection, general health protection, and cannabis-related crime are examined, with the Federal Criminal Police Office participating for the first time in analyzing organized crime. That government representatives and independent experts sometimes draw contradictory conclusions from the same interim results is less a contradiction in the data than evidence of how strongly assessments depend on one’s political starting point.
The crucial observation for our topic: in none of these interpretations is the mortality statistics evidence against legalization, because cannabis simply does not appear in it as a cause of death. How the same report is interpreted differently depending on political stance is shown in more detail in our analysis of the CanG interim report and the black market.
Why the argument is politically so appealing
The force of the drug death argument is explained by the political situation. The Union set out to abolish the KCanG but could not prevail in the coalition; a complete reversal is now considered unlikely, with adjustments being discussed instead. In this constellation, a large, emotionally charged figure like drug deaths is a powerful means of creating pressure for action. This is precisely why a sober look at what the figure says and doesn’t say is worthwhile. A mortality statistic determined by opioids and synthetic substances is not suitable as evidence against the regulation of a substance that does not appear in it.
What concerns remain justified
The fact that the drug death figure doesn’t hold up as an argument doesn’t mean cannabis is harmless or that there are no open questions. Several points deserve serious political attention, independent of the death toll narrative: youth protection and declining reach of early intervention programs, high-dose and unregulated THC products from online retail, driving ability under THC influence, and increased psychosis risk in particularly vulnerable groups and during brain maturation phases. These risks are real and belong in a serious assessment of the law. But they are something different from fatal overdoses.
Why regulation is a safety argument
From a harm reduction perspective, the drug death argument actually reverses the logic. The fatal cases occur overwhelmingly where consumers don’t know what they’re actually taking, such as with counterfeit pills laced with nitazenes. Controlled quality, clear potency information, and low-threshold access to counseling address precisely this risk. For cannabis, this means: purity testing and education reduce risks that remain incalculable on the black market. That cannabis can be contaminated or adulterated on the black market is well documented and a separate reason to view unregulated purchase critically.
International perspective
Legalization opponents like to point to other countries to warn of deaths. The data doesn’t support this warning. Portugal decriminalized drug possession in 2001 and focused on prevention and therapy instead of punishment. The number of drug-induced deaths fell significantly in the long term, from 369 in 1999 to a low double-digit range in the late 2010s; the death rate was recently around six deaths per million inhabitants, well below the European average of just over 20. To be honest, this development was not linear: in the mid-2000s, numbers rose temporarily before falling again. An increase in drug deaths triggered by the reform cannot be derived from this.
Canada legalized cannabis in 2018 for recreational use. While opioid-related deaths there have increased since 2015, research does not attribute this development to cannabis legalization. An analysis found no reliable connection between legal cannabis sales and opioid mortality; the driver of Canada’s crisis is an increasingly fentanyl-contaminated illegal market. Experts also caution in the other direction: cannabis is not a proven remedy for the opioid epidemic. The pattern mirrors the German finding: where drug deaths rise, opioids and synthetic substances are the cause, not the regulation of cannabis.
Conclusion: Debating what matters
Glaubst du, dass die Legalisierung den Drogenkonsum verharmlost?
The claim that rising drug death figures are the price of cannabis legalization does not withstand scrutiny of the data. Deaths are driven by opioids, cocaine, and synthetic substances; cannabis does not appear in the statistics as a cause of death. This doesn’t devalue the political debate; quite the opposite: there can be hard and substantive disagreement about youth protection, product safety, and how regulation is structured. But whoever uses mortality statistics for this is conducting a pseudo-debate. An honest discussion begins by attributing the figures to what they actually represent. We address among other things how greatly the potency and effects of cannabis itself vary in our piece on raw cannabis and THCA.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
